Simple preventive measures like reducing cholesterol and blood pressure should cut the risk of heart disease deaths and hospitalizations by up to 90%, an analysis found.
At the European Society of Cardiology Congress 2016 (ESC), Sigrun Halvorsen, MD, Oslo University discussed the results of her study which analyzed the bleeding rates among NVAF patients who were prescribed anticoagulants.
Adding a PCSK9 inhibitor to apheresis therapy worked so well in reducing LDL in patients with familial hypercholesterolemia that two-thirds of the patients stopped getting apheresis.
At the European Society of Cardiology Congress 2016 (ESC) in Rome, Italy, Michael Lincoff, MD, Cleveland Clinic explained results from ACCELERATE trial involving patients with high risk vascular disease who received evacetrapib on top of standard care.
Renato Delascio Lopes, MD, Duke University Medical Center, discussed at the European Society of Cardiology Congress 2016 (ESC), the progress of anticoagulant therapies for patients.
Experts at the European Society of Cardiology Congress 2016 (ESC) expressed varied opinions on the DANISH trial. Researchers presented that implantable cardioverter-defibrillators (ICDs) do not work for all heart patients.
Not all the news on remote monitoring of cardiac devices was bad at the ESC Congress 2016. Though a UK study had negative findings,Italian researchers said their use reduced office and ED visits and saved patients time and money.
Remote monitoring of heart patients who have implanted heart devices does not appear to help them live longer, a UK study called REM-HF found.
Christopher Granger, MD, Duke University Medical Center also spoke at the European Society of Cardiology COngress 2016 about the issues surrounding patients' tolerability of anticoagulants and other drugs.